scholarly journals Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials

Lab on a Chip ◽  
2020 ◽  
Vol 20 (23) ◽  
pp. 4420-4432
Author(s):  
María Virumbrales-Muñoz ◽  
Jiong Chen ◽  
Jose Ayuso ◽  
Moonhee Lee ◽  
E. Jason Abel ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Blood Vessel ◽  
Cell Carcinoma ◽  
Blood Vessels ◽  
Renal Cell ◽  
Clear Cell ◽  
Single Patient ◽  
Cell Renal Cell Carcinoma

Identification and testing of personalized anti-angiogenic treatments for clear cell renal cell carcinoma using patient-derived microfluidic models of normal and tumor-associated blood vessels.

Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials

2017 ◽  
Vol 15 (6) ◽  
pp. 652-660.e1 ◽  
Author(s):  
Guillermo de Velasco ◽  
Rana R. McKay ◽  
Xun Lin ◽  
Raphel B. Moreira ◽  
Ronit Simantov ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Comprehensive Analysis ◽  
Survival Outcomes ◽  
Cell Renal Cell Carcinoma

scholarly journals Recent advances in the systemic management of non-clear cell renal cell carcinoma: a review article

2020 ◽  
Vol 7 (9) ◽  
pp. 1446
Author(s):  
Soumish Sengupta ◽  
Supriya Basu ◽  
Kadambari Ghosh
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Mtor Inhibitors ◽  
Immunohistochemical Analysis ◽  
Cell Renal Cell Carcinoma ◽  
Drug Of Choice ◽  
Platinum Based Chemotherapy

Non-clear cell renal cell carcinoma (nccRCC) is not as common as clear cell renal cell carcinoma (ccRcc). But then it is not uncommon in regular urological practice. It usually carries a grave prognosis. Authors need to converse ourselves with National comprehensive cancer network (NCCN) categories for evidence and we need to converse as well with NCCN categories for preferences. ‘Preferred intervention’ is based on superior efficacy, safety and evidence and when appropriate, affordability. ‘Other recommended interventions’ are somewhat less efficacious, more toxic, or based on less mature data or significantly less affordable for similar outcomes. ‘Useful in certain circumstances’ are interventions that may be used for a selected patient population. Clinical trials for targeted agents are mainly directed at ccRCC because of its high prevalence. According to the NCCN panel, enrolment in clinical trials is the preferred strategy for nccRCC. Outcomes of patients with nccRCC have improved with the introduction of targeted therapy. Precise pathological diagnosis of the types of nccRCC by immunohistochemical analysis is mandatory. This enables specific treatments for individual nccRCC. Currently TKIs are the drug of choice (both first and second line) for metastatic papillary RCC. Both TKIs and mTOR inhibitors are effective against chromophobe RCC. Platinum based chemotherapy should be used for metastatic CDC. Further evidence is required for management of nccRCC. 

scholarly journals Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications

2007 ◽  
Vol 13 (1) ◽  
pp. 161-169 ◽  
Author(s):  
Xin Yao ◽  
Chao-Nan Qian ◽  
Zhong-Fa Zhang ◽  
Min-Han Tan ◽  
Eric J. Kort ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Blood Vessels ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Prognostic Implications

A SCORING ALGORITHM TO PREDICT SURVIVAL FOR PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A STRATIFICATION TOOL FOR PROSPECTIVE CLINICAL TRIALS

2005 ◽  
Vol 174 (5) ◽  
pp. 1759-1763 ◽  
Author(s):  
BRADLEY C. LEIBOVICH ◽  
JOHN C. CHEVILLE ◽  
CHRISTINE M. LOHSE ◽  
HORST ZINCKE ◽  
IGOR FRANK ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Scoring Algorithm

Analysis of the p53 pathway in clear cell renal cell carcinoma to identify novel drug combinations.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 460-460
Author(s):  
Mark T. Boyd ◽  
Amro Ahmed-Ebbiary ◽  
Radoslaw Polanski ◽  
Aidan Noon ◽  
Keith Parsons ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Drug Combinations ◽  
Wild Type ◽  
Cell Renal Cell Carcinoma ◽  
Mdm2 Antagonist ◽  
Wide Range

460 Background: p53 is rarely mutated in clear cell renal cell carcinoma (ccRCC) with typical mutation frequencies between 0 and 5%. Recent studies have shown that combined p53/MDM2 expression is significantly linked with reduced survival (P<0.0001, HR=3.2) and is an independent prognostic indicator (Cox multiple regression analysis, P=0.027). Studies have also found that p53 is negatively regulated by MDM2 in RCC cells but that rescue of p53 stability is not effective at inducing apoptosis. Studies of normal kidney have shown that signalling to p53 by genotoxic agents is intact, but fail to elicit an apoptotic response. We have therefore investigated a rational combinatorial approach to drug targeting in RCC cells in which both MDM2 is inhibited and apoptosis is stimulated. Methods: Senescence was quantitated by assaying SA-β-galactosidase. Drug sensitivity was determined by measuring MTT conversion at multiple time points. Data from these were used to generate isobolograms and combination indices. Further details of the drugs used will be presented. Results: Using a p53-MDM2 antagonist (currently in clinical trials), our results indicate that in RCC cells rescue of p53 induces some growth arrest and senescence but not apoptosis (IC70 range 7-30 μM). Similarly, using a pro-apoptotic drug (also in clinical trials) which has been demonstrated to promote apoptosis in a wide range of cells, we find little growth inhibitory effect (IC70 range 2.5-30 μM). However, combining a p53-MDM2 antagonist with the pro-apoptotic drug leads to dramatic synergy (combination indices as low as 0.26 [<1 indicates synergy]) and rapid p53-dependent apoptosis in a range of p53 wild-type RCC cell lines. Crucially, the drug combinations have no impact on non-tumour renal cells (neither IC70 nor IC50 could be determined, but both exceed 30 μM) suggesting these may have a high therapeutic index. Conclusions: Rationally designed combinatorial approaches for the treatment of RCC can lead to dramatic enhancement of RCC cell sensitivity and clearly warrant further investigation in both pre-clinical studies (under development) and in clinical trials for RCC due to the retention of wild-type p53 in this disease.

Sign in / Sign up

Export Citation Format

Share Document